Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Medtronic: Receives FDA go-ahead to market its Jewel Plus Active Can (Model 7220C) implantable-cardioverter-defibrillator, the company announces May 10. The 34-joule device incorporates Medtronic's Flashback memory feature, which Medtronic says "provides key information about the history and onset of tachyarrhythmia episodes," and the firm's Marker Channel technology, which "aids precise diagnosis by indicating device response." In addition, the device features a "new interval plotting capability (graphic display of episode characteristics) for stored tachyarrhythmia episodes," the firm says. Medtronic also releases commercially its Transvene tined silicone lead (Model 6934S), which it says is the "world's first tachyarrhythmia lead employing a steroid-eluting electrode to minimize scar-tissue formation at the endocardial wall and thus enhance sensing performance"...

You may also be interested in...



QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.

UsernamePublicRestriction

Register

MT005973

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel